Traditional generics player Glenmark Pharmaceuticals Limited has championed the company’s first innovative product approval in EU markets with its Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray, which is to be sold through a combination of Glenmark’s internal sales force and licensing partner the Menarini Group.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?